Hyaluronan
11 drugs CNSOncology
3
approved indications
11
Approved Drugs
5
Companies
12
Indications
2
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (5 companies)
✓ All 11 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (12 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Roche 5 drugs
Johnson & Johnson 3 drugs
Bristol-Myers Squibb 1 drug
By Therapeutic Area
Oncology 9 drugs
Other 1 drugs
Drugs by Company PRO
Johnson & Johnson 3 drugs
Bristol-Myers Squibb 1 drug
ARGENX BV 1 drug
Merck 1 drug
By Therapeutic Area
Oncology 9 drugs
OPDIVO QVANTIG, RITUXAN HYCELA, KEYTRUDA QLEX, PHESGO +5 more
Other 1 drugs
VYVGART HYTRULO
CNS 1 drugs
OCREVUS ZUNOVO
Indications Treated
Multiple SclerosisRenal Cell CarcinomaMelanomaNon-Small Cell Lung CancerMyasthenia GravisChronic Inflammatory Demyelinating PolyneuropathyBreast CancerFollicular LymphomaDiffuse Large B-cell LymphomaChronic Lymphocytic LeukemiaMultiple MyelomaMetastatic Breast Cancer
All Drugs Targeting Hyaluronan
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| OPDIVO QVANTIG | Bristol-Myers Squibb | 2024 | 3 | Oncology |
| RITUXAN HYCELA | Roche | 2017 | 3 | Oncology |
| VYVGART HYTRULO | ARGENX BV | 2023 | 2 | |
| KEYTRUDA QLEX | Merck | 2025 | 2 | Oncology |
| PHESGO | Roche | 2020 | 2 | Oncology |
| OCREVUS ZUNOVO | Roche | 2024 | 1 | CNS |
| RYBREVANT FASPRO | Johnson & Johnson | 2025 | 1 | Oncology |
| TECENTRIQ HYBREZA | Roche | 2024 | 1 | Oncology |
| HERCEPTIN HYLECTA | Roche | 2019 | 1 | Oncology |
| DARZALEX FASPRO | Johnson & Johnson | 2020 | 1 | Oncology |
| RYBREVANT FASPROI | Johnson & Johnson | 2026 | 1 | Oncology |